Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

GlobeNewswireMay 30 15:25

TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $43

TD Cowen analyst Stacy Ku maintains $Supernus Pharmaceuticals(SUPN.US)$ with a buy rating, and maintains the target price at $43.According to TipRanks data, the analyst has a success rate of 23.8% and

Futu NewsMay 24 07:33

Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $41

Piper Sandler analyst David Amsellem maintains $Supernus Pharmaceuticals(SUPN.US)$ with a buy rating, and maintains the target price at $41.According to TipRanks data, the analyst has a success rate o

Futu NewsMay 24 06:33

Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $38

Stifel analyst Annabel Samimy maintains $Supernus Pharmaceuticals(SUPN.US)$ with a hold rating, and maintains the target price at $38.According to TipRanks data, the analyst has a success rate of 45.5

Futu NewsMay 24 06:33

Piper Sandler Sticks to Its Buy Rating for Supernus Pharmaceuticals (SUPN)

TipRanksMay 24 05:46

Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study

Supernus Pharmaceuticals (SUPN) said data from an interim analysis of a phase 2a study of SPN-817 demonstrated "strong evidence" of clinical utility in epilepsy. The study is examining the safety and

MT NewswiresMay 23 16:23